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ABSTRACT 
 
Somatic mosaicism, defined as the presence of different cell populations with distinct 
genotypes within one individual, caused by post-zygotic errors, has long been considered as a 
source for human genetic variation within and between individuals. It is also plausible that the 
presence of large structural mosaic events could have important implications for human 
diseases. In this study, we provide a genome-wide survey of genetic variation in premature 
ovarian failure (POF) patients by analyzing SNP array data with a novel algorithmic method 
that deciphers mosaic structural alterations. We found mosaic aberrations in 8.2% of samples, 
including 23 mosaic copy number variation (CNV) regions, one mosaic X monosomy and 24 
(larger than 1 Mb) mosaic uniparental disomy (UPD) events. In addition, we were able to 
investigate 23 novel CNVs among patients. 
 
CERCS B220 Genetics, cytogenetics 
Key words: CNV, mosaicism, SNP microarray, premature ovarian failure, POF 
 
 
ABSTRAKT 
 
Somaatiline mosaiiksus on nähtus, kus viljastamisjärgselt esineb üksikindiviidi erinevates 
rakupopulatsioonides erineva genotüübiga rakke. Mosaiiksust on pikka aega peetud 
inimestevahelise ning ka -sisese geneetilise varieeruvuse põhjuseks. Suured mosaiiksed 
struktuursed ümberkorraldused genoomis võivad avaldada mõju indiviidi fenotüübile ning 
olla seeläbi erinevate haiguste põhjuseks. Antud töös teostati kogu genoomi hõlmav uuring, 
avastamaks mosaiikseid ümberkorraldusi enneaegse ovariaalpuudulikkusega patsientidel. 
Kasutades genotüpiseerimiskiipide andmeid ja rakendades uut algoritmilist meetodit, tuvastati 
8,2%-l valimist mosaiikseid aberratsioone, nende hulgas 23 koopiaarvu varianti, üks X 
kromosoomi monosoomia ja 24 (>1 Mb) uniparentaalse disoomia juhtu. Lisaks avastati 
patsientide hulgas 23 uudset koopiaarvu variatsioonide regiooni. 
 
CERCS B220 Geneetika, tsütogeneetika 
Märksõnad: CNV, mosaiiksus, SNP genotüpiseerimiskiip, enneaegne ovariaalpuudulikkus, 
POF 
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ABBREVIATIONS 
 
aCGH   array comparative genomic hybridization 
aUPD   acquired uniparental disomy 
BAF   B-allele frequency 
CN-LOH  copy-neutral loss of heterozygosity 
CNV    copy number variation 
CNVR   copy number variation region 
CNA   copy number alteration 
DGV   Database of Genomic Variants 
DSB   double strand break 
EGCUT  Estonian Genome Center of the University of Tartu 
FISH   fluorescence in situ hybridization 
FoSTeS  fork stalling and template switching 
GWAS  genome-wide association study 
LOH   loss of heterozygosity 
LCR   low copy repeat 
LRR   Log R ratio 
MMBIR  microhomology-mediated break-induced repair 
MMEJ   microhomology-mediated end joining 
NAHR   non-allelic homologous recombination 
NHEJ   non-homologous end joining 
NGS   next-generation sequencing 
OMIM   Online Mendelian Inheritance in Man 
POF   premature ovarian failure 
SCNA   somatic chromosomal and copy number alterations 
SHOX   short stature homeobox 
SNP   single nucleotide polymorphism 
STR   short tandem repeats 
SV   structural variation 
TS   Turner syndrome 
UPD   uniparental disomy 
VNTR   variable number tandem repeats 
WGS   whole-genome sequencing 
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INTRODUCTION 
 
All human individuals are about 99.9 percent identical in their DNA sequence. Understanding 
how that 0.1 percent of human genetic variation influences health and disease is one of 
medical science's highest priorities. However, an adult human organism is composed of ca 
10
14
 cells and it is not surprising that errors can occur at any stages of DNA replication and 
cell division throughout life, producing population of cells, each with its own “personal” 
genome. 
Part of human variability is explained by mosaicism, which describes an individual 
who has developed from a single fertilized egg and has two or more populations of cells with 
distinct genotypes (Strachan and Read, 2011). Mosaic cases are often divided into somatic 
(affecting only non-reproductive cells) and gonadal (affecting germ cells, therefore with the 
potential of being passed on to any offspring) (Biesecker and Spinner 2013). Although the 
majority of changes on somatic DNA level have no obvious consequences, a post-zygotic 
mutation depending on the specific DNA region or the stage of development or type of cells 
involved, can occasionally have an influence on the phenotype of an individual. 
Three main types of structural genetic changes like deletions, gains and copy number 
neutral loss of heterozygosity are known to occur post-zygotically (Forsberg et al. 2013). 
Genome-wide single nucleotide polymorphism (SNP) microarray data collaborated with 
computational algorithmic methods provides an opportunity to detect chromosome variations 
and aberrations as well as somatic mosaic changes within and between individuals. 
Premature ovarian failure (POF) is defined as the cessation of ovarian function before 
the age of 40 years and is therefore one of the causes for female infertility and poor 
reproductive outcome of infertility treatments. As a multifactorial disease its cause remains 
largely unknown, but various data indicate that POF has a strong genetic component. 
As a practical outcome of this thesis is to investigate copy number and copy-neutral 
changes and mosaic chromosomal abnormalities across the genome in premature ovarian 
failure patients. Further aim is to find novel CNV regions and candidate genes related to POF 
phenotype. In addition, we attempt to describe possible mechanisms in which large-scale 
mosaic events might occurred. 
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1. LITERATURE OVERVIEW 
 
Cell is the structural and functional unit of life and the building block of all the living 
organisms. Each human cell contains DNA or the genetic material packaged into 23 pairs of 
chromosomes, of which 22 pairs are autosomes and the other pair is called sex chromosomes, 
determining the gender of humans. DNA carries almost all the genetic information required to 
build and maintain the human body. The gene is the unit of inheritance, determining (a) 
genetic trait(s) and can be passed on during reproduction. The cells adherence to the base-
pairing rules establishes that the new strand is an exact copy of the old one. Although 
replication of the genome is a very precise process and its proofreading capacity minimizes 
the frequency of errors (i.e. mutations), it is not always perfectly accurate and can result in 
errors that may extremely affect the living organism (somatic mutations) or its offspring 
(germ-line mutations). 
 
1.1 Genetic variation 
Genetic variation stems from DNA mutations and can describe differences between the two 
individuals. In addition to the genetic variation that we inherit from our parents and that is 
present in all our cells, DNA changes may occur in the DNA structure of our cells throughout 
life (i.e. de novo mutations). When the frequency of a genetic variant at a specific locus is 
equal or over 1% of subjects in the pool of alleles within a population, it is called 
polymorphism. The variants with frequency of less than 1%, are rather classified as rare 
variants (Frazer et al. 2009). Genetic variations in the human genome can take many forms 
(Table 1, see below), including single nucleotide changes or substitutions; tandem repeats; 
insertions and deletions (known as indels); copy number variations (CNVs); other 
chromosomal rearrangements such as inversions and translocations; and copy-neutral loss of 
heterozygosity (LOH) or homozygosity. These genetic variations are having a wide spectrum 
of sizes, from a single nucleotide (bp) to millions of basepairs, known as megabase (Mb) size 
aberrations. These changes in the human genome can be deemed as the footprints of mistakes 
that occur in DNA replication during cell division, even though external agents, such as 
viruses and chemical mutagens, can also induce changes in the DNA sequence. Regardless of 
the molecular mechanisms or processes that generate the genetic variations, they can be 
generally classified as either somatic or germline variations depending on whether they arose 
during mitosis or meiosis of cell division, respectively (see below) (Ku et al. 2010). 
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The most prevalent form of genomic variation is single nucleotide polymorphisms (SNPs) 
with a frequency of equal or more than 1% in the population. Over 84 million SNPs are 
present in each human genome and most of them have no influence on the phenotype (Auton 
et al. 2015). However, they are useful as genetic markers for genome research to perform 
linkage and association studies due to their high density and the relatively easy methods of 
genotyping. In general, SNPs can occur anywhere on a genome, but much more less 
frequently in coding regions than in noncoding regions. The phenotypic consequence of a 
SNP is related to the location where it occurs, as well as the nature of the variant. However, 
many complex disorders have been associated to common SNPs (Consortium 2004). 
  
Table 1. Types of genetic variants and their approximate sizes. Size ranges are indicative 
only of the scale of each type of rearrangement and are not definitive. Adapted and modified 
from (Sharp et al. 2006). 
 
Variation Rearrangement type Size range 
Single-pair changes SNPs, point mutations 1 bp 
Indels 
binary insertion/deletion events of 
short sequences                            
(majority <10 bp in size) 
1bp -50 bp 
Tandem repeats 
STRs, VNTRs, microsatellites, 
minisatellites and other simple 
repeats 
1bp -500 bp 
Submicroscopic structural 
variation 
deletions, duplications, tandem 
repeats, inversions 
500 bp – 50 kb 
Large-scale structural 
variation 
deletions, duplications, large tandem 
repeats, inversions 
50 kb – 5Mb 
Chromosomal variation 
large cytogenetically visible 
deletions, duplications, 
translocations, inversions and 
aneuploidy 
~5Mb – entire 
chromosomes 
 
Tandem repeats can be broadly divided into two classes: short tandem repeats (STRs) usually 
refer to tandem repeats in which the sequence length is eight nucleotides or less, and longer 
tandem repeats labeled as variable number tandem repeats (VNTRs). These are also known as 
microsatellites (1-6 bp) and minisatellites (10-100 bp), respectively (Denoeud et al. 2003; Ku 
et al. 2010; Sawaya et al. 2013). 
However, apart from single nucleotide changes, such as SNPs, all the genetic 
variations can be broadly grouped under the umbrella of structural variations (SV). The most 
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wide-spread copy number variations (CNVs) can affect chromosomal segments larger than 1 
kilobase (kb) to many megabases (Mb), including entire chromosomes (aneuploidy), which 
are variable in copy number when compared to the reference genome. Copy number 
variations include deletions, duplications and insertions (Feuk et al. 2006). CNVs are 
widespread among humans and account for a nearly ten-fold greater proportion of variation in 
the genome compared to SNPs (Pang et al. 2010). CNVs larger than 40 kb in size account for 
about 18% of the genetic variation in gene expression (Stranger et al. 2007). Copy number 
changes affect approximately seven times as many base pairs as single nucleotide variants and 
are major contributors to interindividual differences (Sudmant et al. 2015). 
The copy number variation map of the human genome, based on CNVs of healthy 
individuals developed from data in the Database of Genomic Variants (DGV) revealed that up 
to 9.5% of the human genome seems to be involved with DNA copy number variation region 
(CNVR) losses or gains (7.5% and 3.9%, respectively). CNVRs were found to be irregularly 
distributed among chromosomes. The average size of these regions are 300-3,000 bp, with 
losses slightly smaller than gains. For gains, chromosome 22, the Y chromosome and 
chromosomes 16, 9 and 15 demonstrated the highest proportion of variability, in contrast to 
chromosomes 3 and 18, which showed the lowest proportion. For losses, chromosomes 19, 22 
and the Y chromosome displays the highest proportion of variable sequence, contrary to 
chromosomes 5 and 8 with the lowest proportion (Zarrei et al. 2015). Common CNVs most 
likely represent genomic regions that can vary without negative consequences. Over the past 
few years, CNVs have attracted much attention due to the fact that they can have dramatic 
phenotypic consequences, including the capacity to alter gene dosage, disrupt coding 
segments, and regulate functional genes. More than 50% of the effects of known CNVs are 
caused by gene disruption or disruption of the regulatory units associated with genes, rather 
than by gene dosage change (Lee and Scherer 2010). 
 Genetic variations are widely used as genetic markers in disease gene mapping, for 
example family linkage and genetic association studies to describe the suscepility loci or 
genes for monogenic and complex diseases (Ku et al. 2010). 
 
1.1.1 Mechanisms of copy number variation formation 
Different mechanisms for formation of CNVs have been described, with different types of 
mechanisms responsible for recurrent and rare CNVs. These include (a) recombination errors, 
like non-allelic homologous recombination (NAHR), (b) mistakes generated in DNA break 
repair, as in non-homologous end joining (NHEJ) and microhomology-mediated end joining 
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(MMEJ) or (c) errors in replication, such as fork stalling and template switching (FoSTes) or 
microhomology-mediated break-induced replication (MMBIR). 
One of the most common mechanism is thought to be NAHR, which is caused during 
mitosis or meiosis by misalignment and cross-over of non-allelic homologous DNA segments 
that can be repetitive sequences such as segmental duplications (SD) or low copy repeats 
(LCRs). Depending on the location and orientation of the homology regions, NAHR can 
cause intra- or inter-chromosomal aberrations (Figure 1). Intra-chromosomal aberrations 
happen within the same chromosome, including deletions and duplications, when they are in 
direct orientation, and inversions, when they are in opposite orientation on the same 
chromosome. However, inter-chromosomal aberrations happen between different 
chromosome, such as translocations induced by LCRs (Inoue and Lupski 2002; Robberecht et 
al. 2013; Sharp et al. 2006). This mechanism of CNV formation is more common in recurrent 
events (Conrad et al. 2010). Somatic NAHR between nonsister chromatids can result in the 
formation of an isochromosome (Barbouti et al. 2004). 
 
Figure 1. Schematic representation of non-allelic homologous recombination (NAHR). 
Repeats oriented in the same direction (A) mediate formation of duplications and deletions of 
the interval between the repeats, while repeats oriented in opposite directions (C) on the same 
chromosome mediate formation of inversions. Repeats on different chromosomes (B) mediate 
formation of translocations. Adapted from (Bailey and Eichler 2006). 
 
The majority of nonrecurrent events are caused by a diversity of mechanisms. Non-
homologous end joining (NHEJ) is one of the predominantly explained mechanism (Figure 2, 
see below), which is a very rapid process that fuses the ends of a double-strand DNA break 
with little or no sequence homology (<4 bp), generating blunt joins or short insertions or 
deletions at the breakpoint junction. Microhomology-mediated end joining (MMEJ) is a form 
of alternative NHEJ. It usually arises when NHEJ and homologous replication repair 
mechanisms are repressed and it is more error-prone than NHEJ. It can lead to deletions and 
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translocations, therefore it is considered as a major source of genomic instability (McVey and 
Lee 2008).  
Second mechanism is called FoSTeS, later included in the generalized mechanism 
MMBIR, has been described as a mechanism for the formation of complex rearrangements 
(Figure 2), as well as inversions, tandem duplications or translocations. The process involves 
stalling of the replication at the fork and shifting of the polymerase by microhomology to any 
nearby single stranded DNA (Hastings et al. 2009a). The involved forks may be adjacent on 
the same chromosome or in a close proximity in three-dimensional space. FoSTeS may cause 
the joining of different sequences from discrete genomic position that are far apart from each 
other. Depending on the direction of the fork progression, the incorrectly joined fragment can 
be in direct or inverted orientation. Furthermore, depending on whether the new fork is 
located upstream or downstream of the original fork, the template switching results in either a 
deletion or a duplication (Zhang et al. 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Genomic rearrangement mechanisms by NHEJ and FoSTeS resulting in 
duplication or deletion. Double-strand breaks (DSBs) are created between the two sequences 
represented as a blue and a red rectangle with no homology between each other. The NHEJ 
mechanism modifies and rejoins the two ends, resulting in the deletion of the segment 
between the two DSBs. FoSTeS mechanism is causing a complex deletion involving two 
fragments. No extensive homology is required between the substrate sequences depicted by a 
blue, a red and a green rectangle. However, the small open triangle heading downwards 
depicts a site bearing microhomology (2-5 bp) between the blue and the red sequences, and 
the small filled triangle heading downwards depicts another site bearing microhomology 
between the red and the green sequences. Adapted from (Gu et al. 2008). 
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Different CNV formation mechanisms are effective in different environments. For example, 
NAHR and NHEJ are effective during meiosis and mitosis, but MMBIR during DNA 
replication. Also, there must be consideration, when studying the CNV breakpoint, that 
NAHR and NHEJ usually correct double-stranded breaks, whereas MMBIR/FoSTeS correct 
single-stranded breaks. These mechanisms may cause deletions and duplications, but MMBIR 
is also able causing inversions, translocations, triplications and loss of heterozygosity (LOH) 
(Conrad et al. 2010). Nonrecurrent CNVs have breakpoints that are not clustered in particular 
genomic regions and are usually formed by NHEJ or microhomology-mediated DNA-
replication errors (FoSTeS or MMBIR) during cell divisions, whereas recurrent CNVs refer to 
genomic-disorder-associated CNVs with clustered breakpoints, usually located in flanking 
LCR regions and mediated by NAHR (Hastings et al. 2009b). The ones that occur at mitosis 
and depending on the developmental stage and cell type can either be restricted to one tissue 
type or present in several or all tissues. For example, somatic mosaicism is the result of 
structural changes during post-zygotic mitosis (Piotrowski et al. 2008). 
 
1.2 Meiosis and mitosis 
The growth and reproduction of all organisms depend on two types of cell divisions, namely 
mitosis and meiosis. Mitosis renders to the majority of the cells via replication and 
segregation of the genomic DNA. The series of events occur in mitosis, called cell cycle, 
yielding two daughter cells. Multicellular organisms are therefore created through many cell 
divisions during the course of the development right after fertilization to a complete organism 
with multiple different tissues and organs.  
In general, cells can be present in two different stages: proliferating (dividing) or 
quiescent (non-dividing). The typical cell cycle is divided into four phases: gap 1 (G1), 
synthesis (S), gap 2 (G2), and mitosis (M) phase, of which the first three phases are 
collectively called interphase. The G1 phase, which begins immediately after the cell division, 
is the primary growth phase where proteins are synthesized and new organelles are formed. 
Once committed to the cell cycle, the next major step is the Synthesis (S) phase, where 
nuclear DNA is replicated (Figure 3A, see below). In the succeeding G2 phase, the cell 
usually continues growing, the machinery for cell division is assembled, and the accuracy of 
the DNA synthesis is tightly controlled. Finally, in the M phase, sister chromatids are 
separated and distributed to the two daughter cells via a process called cytokinesis. The length 
of the cell cycle depends on several factors, including the cell and organ type, developmental 
stage, and physiological conditions. Some cell types continue to divide throughout the life of 
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an organism, while some other cell types remain in a so called non-dividing phase, G0, until 
they receive a signal from the environment to instigate the cycle (Alberts et al. 2014).  
Numerous checkpoints have evolved to ensure that mitosis only proceeds when 
growth conditions are ideal and chromosomes are efficiently replicated and free of damage. 
This level of quality control takes time and for example, proliferating mammalian somatic 
cells require 12–30 hours to properly prepare for division. By contrast, mitosis itself is 
relatively rapid, typically lasting only 20–60 minutes, depending on chromosome number and 
the efficiency of spindle assembly (Yang et al. 2008). However, several mitotic errors may 
occur at any stage of the development leading to large spectrum of genetic mosaicism (see 
below). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The mitotic and meiotic cell cycles. In mitosis (A), diploid cells replicate 
chromosomes during S phase and segregate sister chromatids during M phase. In meiosis (B), 
two chromosome-segregation phases, meiosis I and meiosis II, follow a single round of DNA 
replication during pre-meiotic S phase. During meiosis I, homologous chromosomes (shown 
in red and blue) are segregated to opposite poles. Sister chromatids segregate to opposite 
poles during meiosis II, which results in the formation of non-identical haploid gametes. The 
lengths of the cell-cycle stages are not drawn to scale. Adapted from (Marston and Amon 
2004). 
 
Meiosis is a specialized cell division, characterized by two consecutive rounds of 
chromosome segregation, termed meiosis I (MI) and meiosis II (MII) without an additional 
round of DNA replication (Figure 3B). Pre-meiotic S phase generates two sister chromatids 
per homolog, which are tightly connected along their entire lengths. In meiosis I, the 
homologous chromosomes first pair with one another and normally undergo recombination, 
and then segregate to different daughter cells maintaining the sister chromatids together. Due 
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to the fact that chromosome number is reduced to half this division is also known as 
reductional division. Meiosis I is followed by meiosis II that resembles mitosis, as the sister 
chromatids separate and segregate to opposite spindle poles giving rise to four different 
daughter cells. A crucial player in correct segregation of the homologous chromosomes is 
homologous recombination which happens in MI and instigates genetic diversity in the 
progeny. In most organisms, crossing over in meiosis is required to ensure accurate 
segregation of homologous chromosomes at the first meiotic division. Errors in this process 
can result in random disjunction and aneuploidy, being the leading cause of miscarriages and 
congenital birth defects in humans. Most gametic aneuploidy originates during oogenesis, 
particularly during the first meiotic division, and the frequency of such errors increases with 
female age (Handel and Schimenti 2010; Hassold and Hunt 2001).  
 
1.3 Mosaicism, chimaerism and uniparental disomy 
Part of human variability is explained by chromosomal mosaicism, which have been defined 
as the presence of both normal karyotypes as well as those with large structural genomic 
events resulting in alteration of copy number or loss of heterozygosity in distinct and 
detectable subpopulations of cells (Jacobs et al. 2012). There is variety of different 
mechanisms or processes by which the mosaicism can arise. The unequal distribution of DNA 
upon mitosis may lead to aneuploidy, the duplication or deletion of segments (CNVs) or 
whole chromosomes (aneuploidy), and reciprocal duplication and deletion events that appear 
as copy-neutral loss of heterozygosity (CN-LOH) or acquired uniparental disomy (aUPD) 
(Jacobs et al. 2012). Some types of structural mosaic changes are also schematically shown in 
Figure 6 (see page 20). These mutational processes can occur at any stage of development: in 
stem cells, differentiating cells, and in terminally differentiated somatic cells (Lupski 2013). 
Depending on the point at which a mutation occurs, the aberrant cell population may exist in 
only a specific part of the body, e.g. one organ, one tissue or even a part of that tissue 
(Biesecker and Spinner 2013). As mosaicism can arise through any type of post-zygotic 
alteration, it is right to claim that we are all genetically mosaic, as everyone has at least one 
cell in their body that differs from the others.  
The consequences of mosaicism depend on how it modifies genetic architecture and 
more specifically development and cell-specific pathways (Rodríguez-Santiago et al. 2010). 
Somatic mosaicism may affect different tissues at variable levels. For example, depending on 
the timing at which the alteration occurred, as well as the affected gene and whether it is 
expressed in that certain tissue. In addition, the survival capacity of the mutant cells is also 
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important (Cohen et al. 2015). There can be wide range of phenotypic impact of mosaicism 
for the individual. The majority of somatic mosaic changes have been described in relation 
with a known phenotype, which represent mosaic aberrations with strong effect, but the 
mosaicism can result in either milder or unusual disease phenotype as well. If mosaic somatic 
changes have no visible phenotypic effect, it is suggested that the occurrence of mosaicism 
events is underestimated because of deficiency of common detection methods (Rodríguez-
Santiago et al. 2010). 
Mosaic aneuploidy is the most common type of mosaicism (Hassold and Jacobs 1984). 
In some inherited diseases, the mosaic form is phenotypically less severe than the 
constitutional form, e.g. mosaic trisomies 13, 18 and 21 have less severe phenotypic 
consequences when compared to full trisomic ones. Other mosaic trisomies reported include 
trisomy 8, 9, 14, 17 and 22 (Daber et al. 2011; Hassold and Jacobs 1984). Aneuploidies of the 
sex chromosomes are more common than autosomal aneuploidies and the post-zygotic gain or 
loss of an X or Y chromosome results in somatic mosaicism, e.g. the mosaic forms of 
Klinefelter syndrome or mosaic Turner syndrome (TS) (Hersmus et al. 2012; Jacobs et al. 
1997). Mosaic forms of other structural variants such as translocations, inversions, ring 
chromosomes and supernumerary chromosomes are not as commonly reported (Biesecker and 
Spinner 2013).  
Studies on human embryos have also shown that mosaicism for chromosome 
anomalies is detected in 50-80% of all human embryos generated following in vitro 
fertilization (IVF) (Bielanska et al. 2002; Zamani Esteki et al. 2015; Vanneste et al. 2009). 
The loss or gain of entire chromosomes is thought to be caused by errors in chromosomal 
segregation in anaphase during mitosis, while non-allelic homologous recombination (NAHR) 
may cause the gain or loss of large genomic regions (Liu et al. 2012). The phenotypic effects 
of these reorganizations vary based on the genomic region and the size of the event. 
Mosaicism has been stated in normal aging, also as a cause of miscarriage, birth defects, 
developmental delay and cancer (Conlin et al. 2010; Hassold 1982; Hsu et al. 1992; Jacobs et 
al. 2012; Laurie et al. 2012; Lu et al. 2008; Menten et al. 2006). Forsberg et al., suggested that 
post-zygotic variation may explain a notable part of the cause of non-heritable diseases 
(Forsberg et al. 2013). 
Mosaicism is different from chimaerism, which exists when an individual carries cell 
lineages from multiple zygotes. Examples of chimaerism include cells remaining in a 
recipient after an organ transplantation; chimaerism can also occur in twins when there is 
fusion of two different zygotes resulting in a single embryo; or after fertilization by two sperm 
of an oocyte and a polar body (Bluth et al. 2007; Khan et al. 2004; E. J. Yunis et al. 2007). 
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Chimaerism would not be detectable by standard cytogenetic technology. The use of a 
genome-wide SNP array makes the differentiation between mosaicism and chimaerism 
possible together with novel genome analysis methods, as the allelic admixtures can be 
identified within the B-allele frequency (BAF) profiles (Conlin et al. 2010; Destouni et al. 
2016; Zamani Esteki et al. 2015). 
Uniparental disomy (UPD) is a type of copy-neutral structural variation. It occurs 
when two homologous chromosomes, or segments of chromosomes, originate from a single 
parent, instead of one copy each coming from the mother and father (Engel 1980). UPD can 
either be constitutional (germline lesion) or acquired (aUPD) in somatic cells. Acquired 
uniparental disomy (aUPD), also known as copy-neutral loss of heterozygosity (CN-LOH) 
have reported in numerous studies as a common feature in a variety of human cancers 
(Dunbar et al. 2008; Walsh et al. 2008). There are at least four primary mechanisms by which 
UPD can occur for segmental or whole chromosomes (Figure 4): (1) trisomy rescue, for 
example, mitotic loss of one of the three copies of the trisomic chromosome; (2) monosomy 
rescue, for example, duplication of the single copy of a chromosome pair via nondisjunction; 
(3) post-fertilization error by either mitotic nondisjunction followed by reduction of the single 
homologue or vice versa; (4) gamete complementation, whereby a gamete missing one 
chromosome pair unites with a gamete containing two copies of the same chromosome pair 
by chance (Eggermann et al. 2015; Engel 2006). 
 
Figure 4. The schematic illustration of the mechanisms leading to UPD formation and 
possible mosaic constitutions. Mechanisms include trisomy rescue (A), monosomy rescue 
(C), gamete complementation (C) and post-fertilization mitotic error (D). Adapted from 
(Eggermann et al. 2015). 
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There are no apparent phenotypic effects from UPD for most chromosomes, but there are a 
few chromosomes that involve parent-specific imprinting and have clinically recognizable 
phenotypic effects when involved in UPD. Currently, maternally derived chromosomes 7, 14 
and 15 and paternally derived chromosomes 6, 11, 14 and 15 are the only examples of definite 
phenotypic effect due to UPD and imprinting. Chromosomes 2, 16 and 20 are also being 
studied but it is unclear what are their exact phenotypic effects due to imprinting (Shaffer et 
al. 2001). As an example, UPD can cause disease through the biallelic silencing or biallelic 
expression of an imprinted gene. Segmental paternal UPD for a portion of chromosome 
11p15.5 is a cause of Beckwith–Wiedemann syndrome (BWS) in 10–20% of patients. The 
11p UPD is always mosaic, and it has been hypothesized that UPD for this region may be 
lethal early in development (Cooper et al. 2007; Romanelli et al. 2011). 
CN-LOH or aUPD can occur in two different ways: loss of one chromosome followed 
by duplication of the remaining chromosome (with the homologous chromosomes arising 
either maternally or paternally) leads to whole chromosome aUPD, whereas somatic 
recombination leads to segmental aUPD. In both cases, aUPD has the potential to lead to loss 
of heterozygosity of existing aberrations such as mutation, deletion, methylation, histone-
modification, or imprinted genes (Tuna et al. 2015). Because of the lack of copy number 
change, CN-LOH cannot be detected by conventional cytogenetics, but during the past 
decade, significant advances in genome-wide SNP arrays have provided strong resolution and 
greatly simplified assay of CN-LOH (Score and Cross 2012). Žilina and colleagues studied 
panels of tissue samples (11-12 tissues per individual) from four autopsy subjects using high-
resolution SNP arrays to reveal the presence of possible intra-individual tissue specific CN-
LOH and CNV patterns. They detected five mosaic CN-LOH regions over 5 Mb in some 
tissue samples in three out of four individuals. These results give further support to the idea 
that somatic mosaicism for CN-LOHs is a common phenomenon in phenotypically normal 
individuals (Žilina et al. 2015). 
 
1.4 Strategies for detection of genomic aberrations 
There are several methods (Table 2, see below) that have been used for detection of 
chromosomal aberrations and each of them has different throughput, coverage and resolution. 
The development of chromosome banding techniques, in which segments of euchromatin and 
heterochromatin are differentially stained, enabled the identification of large structural 
changes on chromosomes. The most common chromosomal banding technique, high 
resolution G-banding was invented in 1978 (Yunis et al. 1978) and enabled the detection of 
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structural changes that are at least 5-10 Mb in size and is still used nowadays for clinical 
diagnostic testing.  
 
Table 2. Experimental methods to detect structural variation. Adapted and modified from 
(Vandeweyer and Kooy 2013) 
 
Method Karyotyping FISH aCGH SNP array 
NGS (paired-end 
mapping) 
Type microscope microscope microarray microarray sequencing 
Translocation >3 Mb yes no no yes 
Inversion >3 Mb yes no no yes 
Deletion >3 Mb >200 kb >5 kb >5 kb yes 
Duplication >3 Mb >200 kb >5 kb >5 kb yes 
UPD no no no yes yes 
Sequence no no no yes (SNP) yes 
 
Traditional cytogenetics, such as karyotyping, is able to detect large balanced and unbalanced 
numerical and structural chromosome aberrations, but copy-neutral loss of heterozygosity 
(CN-LOH) is not visible. Karyotyping can also detect mosaic structural abnormalities, but this 
process is laborintensive, e.g. 14 cells must be examined per individual to exclude 10% 
mosaicism with 95% confidence (Hook 1977). 
Molecular cytogenetics, however, enabled more accurate screening of the genome. 
The trend has started with probing a few marker at a time via fluorescent in situ hybridization 
(FISH) to hundreds of thousands markers at a time via microarray technologies and now 
basically every single nucleotide of the genome can be screened with the advent of next-
generation sequencing (NGS). Fluorescent in situ hybridization offers improved resolution 
compared to karyotyping and interphase FISH can be performed without cultured cells. 
Metaphase FISH, which is culture-dependent method, enables concurrent visualization of a 
structural aberration and the chromosomes. Although FISH allows a better resolution in 
detecting smaller genomic abnormalities (approximately 80-200 kb), when compared to 
traditional methods such as G-banding, this approach is limited. Only a few FISH probes can 
be used in this assay and therefore it lacks whole-genome coverage and requires prior 
knowledge of certain region to identify the clinical value of the test. FISH is still used today 
for detection of unbalanced translocations and also for independent validation for other 
methods (Levsky and Singer 2003). 
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Comparative genomic hybridization (CGH) is a technique in which fluorophore-labeled DNA 
from a control and test individual are hybridized to a metaphase reference chromosome 
(Kallioniemi et al. 1993). The same rationale has been applied in the development of array 
comparative genomic hybridization (aCGH), which quantifies the frequency of thousands to 
millions of probes across the genome of the DNA samples, as it allows measuring the 
intensity of light emitted by fluorescent probes hybridized to a DNA sample when compared 
to the control(s).  
In general, there are two formats of microarray, albeit with different chemistries: (1) 
two-channel platform aCGH and (2) one-channel platform, single nucleotide polymorphism 
(SNP) microarray. Specifically, in aCGH DNA from test and reference samples are labeled 
with different fluorophores and then competitively hybridized to a microarray including 
hundreds to millions DNA probes that are complementary to targeted genomic regions. 
Whereas, SNP array technology relies on hybridization of one sample to an array and the 
results of that hybridization is compared in silico to a database of standard reference DNA 
(Pinto et al. 2011). SNP array technology has the advantage of detecting not only copy 
number gains and losses but also loss of heterozygosity regions, e.g. uniparental disomy 
(UPD). Importantly, SNP array has the capacity of detecting mosaic allelic architectures 
across the genome. These technologies are cell-culture free, the mosaicism is more easily 
detected because of thousands of cells are assayed simultaneously (Bruno et al. 2011; 
Oostlander et al. 2004). Despite these facts, robust computational methods are required to 
detect copy number and copy-neutral anomalies and different levels of mosaic aberrations 
(see below). 
Next generation sequencing (NGS) techniques have revolutionized sequencing 
possibilities. NGS includes whole-exome sequencing (WES), whole-genome sequencing 
(WGS), and targeted sequencing approaches. Each NGS technique starts with creating a DNA 
library by fragmenting genomic DNA and amplifying it. Using synthetic oligonucleotides, the 
fragments can be attached to a sequencing media (for example, glass) and amplified, 
generating many clones of fragments. Fragments are denaturated and imaging techniques 
capture growing strands and record strings of bases, of which each contains bases from a 
location in the genome. WGS can detect different types of copy number variation, CN-LOH 
and balanced translocations, providing very complete resolution of heterogeneous sample. 
The unique paired-end sequencing by lllumina usually allows detection capacity in base pair 
resolution for the detection of deletions, duplications, inversions and insertions (Campbell et 
al. 2008). On the other hand, if there is a purpose to detect mosaic mutations, the achievement 
of high coverage of the genome makes the technology expensive. In any next generation 
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sequencing approach, the analysis of the large amounts of generated data is currently the most 
challenging part of the process. This is also a major reason why the NGS technique has been 
implemented to the clinical setting slowly and with caution (Desai and Jere 2012). 
 
1.4.1 SNP array-based detection methods for mosaic chromosomal abnormalities 
It has been proven that SNP-array technology has the capacity of detecting a large spectrum 
of genetic disorders, including mosaic and/or chimeric genomic aberrations (Conlin et al. 
2010; Destouni et al. 2016; Jacobs et al. 2012). SNP arrays provide an intermediate option 
between traditional cytogenetics and whole-genome sequencing (WGS). The detection of 
mosaic events in SNP array platform is based on assessment of allelic imbalance and copy 
number changes. The chromosomal abnormalities detected by Illumina SNP arrays are based 
on two main data tracks (Figure 5): summed allelic intensity, which is demonstrated by log R 
ratio (LRR) and allele balance, which is demonstrated by B-allele frequency (BAF).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Expected LRR and BAF values for different copy number and copy number 
neutral changes. LRR plot describes the copy number state and BAF plot illustrates the SNP 
genotypes. M – maternal chromosome; P – paternal chromosome. The scatter of points 
demonstrate homozygous deletion (copy number = 0). Adapted from (Laurie et al. 2012). 
 
For each probe on the SNP array, LRR is the normalized log2 ratio of the observed signal 
intensity to the expected signal intensity (Peiffer et al. 2006). If the DNA sample is normal 
diploid, LRR value is zero and any deviations from zero indicate copy number change. BAF 
is the fraction of B allele over both alleles (A allele + B allele). For normal diploid genomic 
regions, heterozygous AB SNP genotypes have BAF value of 0.5, while homozygous AA or 
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BB SNP genotypes have BAF value of 0 or 1, respectively and any deviations from these 
values are indicative of structural aberrations (Figure 6) (Wang et al. 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Post-zygotic structural genetic aberrations: mosaic aUPD/CN-LOH (a), mosaic 
trisomy (b) and a mosaic deletions (c, d), respectively. The results consist of two data 
tracks: log R ratio (LRR) and B-allele frequency (BAF), as described above. Panel A shows a 
mosaic aUPD for distal 12q with lack of changes in LRR value and BAF deviations from 
value 0.5. Panel B displays mosaic trisomy for chromosome 19, where is a narrow split in the 
intermediate BAF band and LRR demonstrates only a small elevation. Panel C illustrates a 
mosaic deletion at 20q with a small decrease in LRR and narrow cleavage from intermediate 
BAF band. Panel D demonstrates also a mosaic deletion at 6q, but with a wider split in BAF 
band and larger decrease in LRR compared with panel C. Adapted from (Laurie et al. 2012). 
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1.5 Large scale studies of chromosomal mosaicism 
In 2010, Conlin et al. examined blood from 2,019 children with pervasive developmental 
delay or congenital abnormalities, identifying 12 with mosaic aneuploidy (0.6%) and eight 
with UPD. Of these eight UPD events, four were from trisomy rescue, two were from 
monosomy rescue, and two were mitotic in origin. Mosaicism was only detected in the two 
mitotic cases. The origin of the other six UPD events was inferred from the allele fraction 
patterns. Of the 12 aneuploidies, 9 were monosomies, and all of these monosomies arose from 
mitotic nondisjunction suggesting that early stage (inherited) monosomy is lethal, while half 
of the trisomies arose by meiotic nondisjunction. In addition, one of the children with a 
mosaic abnormality was chimeric (Conlin et al. 2010). 
SNP array data were also used by several studies that directly analyze the rate of 
somatic segmental copy number variation and CN-LOH in the general population. Laurie et 
al. analyzed over 50 000 samples from 15 different case-control GWA studies (GWAS) 
collected as part of the GENEVA (Gene-Environment Association Studies) consortium. The 
studied phenotypes included cancers and non-cancer conditions, and the subjects had a wide 
range of ages, from newborns to individuals more than 80 years old. They found that the 
prevalence of a detectable mosaic event was low for younger age groups, but increased to 2-
3% for subjects more than 80 years old. They also found a ten-fold increased risk of 
hematological cancer for individuals with detectable blood mosaicism compared to subjects 
without detectable blood mosaicism, suggesting that mosaic mutations may be a biomarker 
for cancer risk (Laurie et al. 2012). Jacobs et al. also found that the prevalence of mosaicism 
increased to about 2% in cancer-free individuals older than 75 years, and found an even 
stronger relationship between blood mosaicism and incident hematological cancer (Jacobs et 
al. 2012). 
The largest analysis of 127,000 adults, which focused on events >2 Mb, showed an 
overall rate of mosaic events of 0.73%, of which approximately half of the detected events 
were mosaic copy number neutral uniparental disomy (48%), followed by mosaic losses 
(34%) and mosaic gains (17%). 14% of the individuals had multiple events. The mosaic 
changes showed an oblique chromosomal distribution: gains were most common in 
chromosomes 8, 12 and 15, losses affected mainly chromosomes 13 and 20, and the most 
common mosaic UPDs involved chromosomes 9 and 14. Gains and losses involved a higher 
proportion of cells than copy-neutral events. Mosaic events were rare in individuals under the 
age of 50. Their frequency was six-fold higher in individuals aged over 75, suggesting that 
mutant clones expand with age (Machiela et al. 2015). 
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Recently, Vattathil and Scheet applied a computational method using estimated haplotypes to 
characterize mosaic structural mutations in 31,100 GWAS subjects (Vattathil and Scheet 
2016, Supplementary). They investigated 2.9% somatic copy number alterations (SCNAs) of 
all samples. There were 70 gains, 202 hemizygous losses, 30 CN-LOHs and other were left 
unclassified. They also provided additional survey with previously identified somatic 
mutations by Laurie et al., but they used hapLOH haplotype-based approach and identified 
larger number of SCNAs, 794 of them were unique (1093 vs 379). The study also confirmed 
that SCNA prevalence is positively associated with age, in their results over 80-years old 
individuals it is approximately 80% (Vattathil and Scheet 2016). Examples of microarray 
studies of mosaicism are summarized in Supplement 1. 
 
1.6 Female reproductive system, ovarian reserve and fertility outcome 
Healthy ovarian function is essential for the general health of a woman and for the production 
of sex steroids, which are needed for the development of the genital tract and for bone density 
(De Vos et al. 2010). In the embryo, primordial germ cells (PGCs) migrate from the yolk sac 
to the urogenital ridge at around 5 and 6 weeks (Mamsen et al. 2012), which in the female 
embryo become the ovaries containing a non-renewable reserve of germ cells. According to 
traditional standpoint the human ovary holds a decreasing reserve of oocytes from fetal life 
until the woman enters menopause. The oocyte quantity reaches its peak already before birth, 
with approximately seven million follicles (Figure 7). At birth the number decreases to around 
1-2 million and at the onset of puberty only 300,000-400,000 follicles are left.  
 
 
 
 
 
 
 
 
 
 
Figure 7. Reduction of ovarian follicular pool during a woman’s life. Shaded area 
indicates level of follicle population at which ovarian failure or menopause occurs. p5=5th 
percentile, p50=median, p95=95th percentile. Adapted from (De Vos et al. 2010). 
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When the woman enters menopause at an average age of 51, approximately 1000 follicles 
remain in the ovary (Faddy and Gosden 1996). During the reproductive life of a woman, 
approximately 400 of the original follicles will ovulate and at the vast majority will undergo 
atresia by apoptosis (Vaskivuo and Tapanainen 2003). Besides the decrease in follicle 
number, also the quality of follicles and oocytes decline with age, exhibiting structural 
damage and aneuploidy with an increasing frequency (de Bruin et al. 2004). 
As social and economic development has increased during the last century, there has 
been a substantial decline in fertility rates (Myrskylä et al. 2009). Ovarian ageing and its 
associated effects on fertility has received greater attention as an increasing number of women 
in modern society choose to postpone the age at which they bear children. Age is a crucial 
factor affecting female’s fertility and reproductive outcome. Older women have to face the 
natural limits of their own reproductive system, due to the fact that fecundity is reduced with 
increasing female age (Broekmans et al. 2007). Over the past 20 years, the median age of 
women at their first birth in Estonia increased from 22.8 to 26.5 (Eurostat database)
1
. A 
similar trend has been noted all over the Europe, where data shows an average median age at 
first birth almost 29 years of age. Up to 10% of women in the general population are 
estimated to become menopausal by the age of 45 and 1% before the age of 40 (Nikolaou and 
Templeton 2004). 
 
1.7 Premature ovarian failure 
Premature ovarian failure (POF), also known as primary ovarian insufficiency (POI), refers to 
development of amenorrhea due to cessation of ovarian function before the age of 40 years 
with a prevalence about 1% in women under the age of 40, and 0.1% in women under the age 
of 30 (Coulam et al. 1986). From a clinical point of view, POF has been defined as 4–6 
months of amenorrhea, a rise in serum follicle-stimulating hormone (FSH) levels to greater 
than 40 mIU/L, and hypoestrogenism (Goswami and Conway 2005). POF is one of the causes 
for female infertility and has a poor reproductive outcome of infertility treatments (de Boer et 
al. 2003). As a consequence of hypoestrogenism, POF is associated with a greater risk of 
osteoporosis, osteoarthritis and cardiovascular disease (Shuster et al. 2010). 
Despite the presence of numerous studies, the pathophysiological development of POF 
remains unknown in most cases. The disorder is heterogeneous: possible causes include 
chromosomal abnormalities, gene mutations, autoimmunity, metabolic disorders, infections 
and iatrogenic treatments like ovarian surgery, radiotherapy or chemotherapy that somehow 
leads to follicle dysfunction or depletion (Nelson et al. 2009). POF usually appears 
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sporadically, but there can be also a family history in 4-30% of cases (Conway et al. 1996; 
Vegetti et al. 1998). 
Chromosomal abnormalities include numerical defects like monosomy X or X 
chromosomal mosaicism, X deletions, X-autosome translocations, X-isochromosomes and 
other rearrangements. The prevalence frequency of these anomalies based on different studies 
is between 10-13% (Qin et al. 2015). Both, X chromosome and autosomes, has a wide range 
of candidate genes causing non-syndromic premature ovarian failure (see Supplementary 
Table 1 and 2 from Qin et al. 2015). Distinct from non-syndromic POF, in some patients POF 
appears to be associated with another syndrome (syndromic POF) that may manifest the 
disorder as part of their phenotypic spectrum. The most common single genetic explanation 
for premature ovarian failure is represented by Fragile X syndrome. Around 21% of cases of 
familiar POF are associated with the premutation of FMR1 gene (MIM*309550)
3
, located in 
the X chromosome (Sullivan et al. 2005). There are also remarkable numbers of genome-wide 
approaches to locate susceptible loci or genes causing POF, but there are notable imbalances 
among different populations (see Supplementary Table 5 from Qin et al. 2015). 
Our lab performed genetic association study to investigate the potential associations 
between copy number variations and the onset of premature ovarian failure using Estonian 
population-based biobank samples. In addition to the three regions investigated before, in this 
study, 15 novel rare microdeletion and microduplication regions were found that may 
contribute to spontaneous POF. Among the genes found in the novel regions are for example 
FMN2 (1q43), SGOL2 (2q33.1), TBP (6q27), SCARB1 (12q24.31), BNC1 (15q25) and 
ARFGAP3 (22q13.2). These genes are essential for meiotic progression or in follicular growth 
and oocyte maturation, respectively. This study confirmed that CNVs have possible role in 
pathogenesis of POF (Tšuiko et al. 2016). 
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2. EXPERIMENTAL PART 
2.1 Objectives 
The present study was carried out with the following primary objectives: 
 
1. Detection of copy number alterations in POF patients: 
The detection of DNA copy number changes, including duplications and deletions across the 
genome of POF patients following whole-genome genotyping by SNP-array technology. 
 
2. Detection of copy-neutral alterations in POF patients 
The prevalence of DNA copy-neutral loss of heterozygosity (CN-LOH) across the genome in 
POF patients versus the controls.  
 
3. Detections of mosaic abnormalities in POF patients 
The assessment of somatic mosaic changes, including mosaic deletions, duplications and 
UPDs, and their degree of mosaicism in POF patients and in the controls. 
 
2.2 Materials and Methods 
2.2.1 Study Objects 
Participants of the study were selected from the biobank of EGCUT (Estonian Genome 
Center, University of Tartu) on the basis of the phenotype information. In total, we analysed  
587 women with spontaneous premature ovarian failure, of which 345 were classified as 
cases, who has secondary amenorrhea occurred before the age of 40 and the remaining 242 
women are with iatrogenic manipulation, especially gynecological operation causing 
amenorrhea. The latter cohort are classified as controls in this particular study. In addition, we 
also used Estonian general population samples genotyped with Illumina HumanOmniExpress 
BeadChip arrays (N=5132) from EGCUT to exclude benign population-specific CNVs. 
 
2.2.2 SNP genotyping by the use of SNP-array technology 
HumanCoreExome and HumanOmniExpress BeadChip arrays (Illumina Inc.) were used for 
genotyping. The HumanOmniExpress BeadChip contains >715,000 SNP markers with 
median marker spacing of 2.1 kb, while HumanCoreExome BeadChip has 547,644 markers, 
with 265,919 of them being focused in exome regions, and a median marker spacing of 1.9 
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kb. Sample processing and assay preparation were performed according to manufacturer 
protocols in EGCUT Genotyping Core Facility. 
 
2.2.3 Algorithmic methods used for detection of genomic abnormalities 
We have initially analyzed the SNP-array data by Illumina’s GenomeStudio software 
Genotyping Module v.3.1. A call rate of >98% was accepted as the primary quality control for 
each sample. Log R ratio (LRR) and B-allele frequency (BAF) at each SNP loci are two 
important types of values for CNV detection. LRR and BAF information was analyzed with 
an algorithmic method which is conceptually similar to haplarithmisis (Zamani Esteki et al. 
2015). The algorithm detects allelic imbalances by decifering both LRR and BAF values, with 
the capacity of revealing (mosaic) copy number and copy-neutral abnormalities across the 
genomes. 
 
2.3 Results 
2.3.1 Copy number alterations in POF patients 
Total of 345 samples of premature ovarian failure patients cohort were analysed for detection 
of genome-wide copy number changes. LRR information indicated four patients with 
monosomy X (Turner syndrome) and one control with trisomy X (Triple X syndrome), which 
were exluded from the following analyses. Subsequently, we compared all the detected CNV 
regions of the patients with the controls. All overlapping regions were left out and 122 non-
overlapping copy number variation regions (CNVRs) were remained. Additional quality 
filters were applied after obtaining remaining regions. CNVs that were less than 100 kb were 
excluded from the following data analyse against population-based CNVs from EGCUT 
(N=5132). Confidence interval for this analyse was CI=30. Elevated values provide better 
insight and reliability as well maximise accuracy for further analyse. Results from comparison 
of 40 CNVRs (>100 kb) against benign CNVs (N=5132) revealed 23 potentially novel CNV 
regions (Table 3, see below), 17 of these overlapped with population-based CNVs. 
In detail, in the evaluation of 345 POF patients, this analysis indicated a total of 23 
new CNV regions and included 16 copy number losses (70%) and 7 copy number gains 
(30%) ranging from 100 kb to 7,5 Mb in length (mean=672 kb, median=191 kb). In addition, 
our data shows that losses are more frequent than gains. 
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In previous research with spontaneuos POF patients, total of 55 microduplications or 
microdeletions were found (Tšuiko et al. 2016, Supplementary) and 15 of them were found to 
be relevant to POF condition. The second important matter is that nine of these 15 regions 
were probabaly excluded by our patient-control comparison or analysis against population-
based CNVs. Tšuiko et al. considered CNVs as benign if these were present >1% of the 
population, but we decided to excluded all overlapping regions. In our analysis, however, we 
were able to detect 70,6% of the same regions, of which 20% were mosaic. Improtantly, we 
detected 11 novel (Table 3, blue rows) CNV regions (findings not validated) from the same 
cohort of patients and these novel aberrant regions were studied along with other detected 
regions using the UCSC Genome Browser database
2
 to evaluate the potential clinical 
relevance to POF of a particular CNV. 
 
Table 3. Overview of CNV regions (N=23) identified in this study. Novel variants (N=11) 
from the same cohort of POF patients examined before are presented in blue rows. 
 
Chr Band Start Stop Length (bp) Change 
2 p25.3 1116648 1584345 467697 Deletion 
2 p22.3 35597319 35709163 111844 Deletion 
2 p11.2 89918400 90109261 190861 Deletion 
2 q13 110863908 110983320 119412 Deletion 
3 q29 197581268 197833758 252490 Duplication 
4 p16.3 60055 171534 111479 Duplication 
4 q13.3 69434042 69537475 103433 Deletion 
4 q23 99363155 99510279 147124 Deletion 
4 q24 102839161 103023963 184802 Deletion 
5 p15.32 6021846 6136125 114279 Deletion 
7 p22.3 2159817 2310974 151157 Deletion 
7 q36.3 158456893 159119220 662327 Duplication 
8 p23.3 163226 1178457 1015231 Duplication 
9 p22.1 19074820 19281501 206681 Duplication 
9 p12 39004140 39151736 147596 Deletion 
13 p12 114507886 115091330 583444 Duplication 
14 q12 27071318 27393217 321899 Deletion 
15 q25.1 80500456 80642236 141780 Duplication 
16 p13.3 95254 2305539 2210285 Deletion 
16 p13.3 84529382 84630053 100671 Deletion 
18 q22.2-q23 70467981 78014582 7546601 Deletion 
19 p13.2 8969269 9298364 329095 Duplication 
21 q21.2 24166144 24400039 233895 Deletion 
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2.3.2 Copy number neutral alterations in POF patients 
Copy-neutral LOHs were assessed using our algorithmic method. Visual inspection of the 
profiles deduced by the algorithm revealed that the approximate copy-neutral events across 
the genomes of both patients and controls are relatively high. We counted the CN-LOHs of 
every chromosome in both group and divided it with the size of the each cohort (Figure 8). 
Following this analysis, we could not find a significant difference between these cohorts. 
Interestingly, we observed relatively large CN-LOH regions in chromosomes 2, 3, 7, 17 and 
22 in one POF patient. Demonstrations of these events with approximate sizes are shown in 
Supplement 4.  
 
 
Figure 8. Proportions of CN-LOH events by chromosome from patients and controls. X 
axis – chromosome number, Y axis – total of CN-LOH events seen by chromosome divided 
with number of samples from patients or controls, respectively.  
 
2.3.3 Mosaic abnormalities in POF patients 
We also identified mosaic copy number gains and losses, as well as mosaic copy-neutral UPD 
events. For mosaic CNAs, each sample was explored for BAF values [BAF_G (greater), 
BAF_L (lower)] together with LogR in the same chromosomal region. Based on the values 
seen in the data, we were able to determine degree of mosaicism and the type of alteration 
(gain or loss). Degree of mosaicism was determined as described by Conlin et al. 
(Supplement 2). First, all mosaic findings were compared between patients and controls. All 
non-overlapping events (comparison of the LogR values) that were larger than 100 kb were 
analysed against population-based cohort (N=5132) to exclude benign copy number changes 
to distinguish correct mosaic changes. 
Results from this analysis left only 24 mosaic events (Table 4, see below) for further 
investigation. In patients, 13 mosaic duplication (54,2%) and 2 mosaic deletions (8,3%) were 
found. One of these deletions, however, is the most significant finding of mosaic monosomy 
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for chromosome X (Figure 9, see below). In control group, these numbers were 8 (33,3%) and 
1 (4,2%), respectively. 
 
Table 4. Results of mosaic copy number abnormalities (N=24) detected in this study. 
White rows are representing the results from patients and blue rows from controls group. 
Mosaic findings that were the same with the CNV regions investigated in previous POF 
cohort study are bolded.  
 
Chr Band Start Stop Length (bp) 
Mosaic 
% 
Change Subject 
2 
p22.2-
p22.1 
36775797 38580233 1804436 40 deletion patient 
2 q21.2 133225803 133902333 676530 45 duplication patient 
2 q33.1 200250898 201845999 1595101 40 duplication patient 
3 p26.3 1577232 2667189 1089957 40 duplication control 
3 q29 195479250 195877603 398353 45 duplication patient 
4 p16.1 10188326 11112475 924149 45 duplication patient 
4 q28.1 127041554 127649306 607752 40 duplication patient 
4 
q34.1-
q34.2 
174961164 175658175 697011 45 duplication control 
5 p13.2 33955326 34753340 798014 40 duplication patient 
7 p11.2 55798357 56504381 706024 45 duplication control 
10 q26.3 132547184 133057358 510174 40 duplication patient 
11 
p11.12-
p11.11 
50070332 51372036 1301704 40 duplication patient 
12 p13.33 1017830 1517350 499520 45 duplication control 
12 q24.33 133448936 133810935 361999 40 duplication patient 
16 q23.1 76986417 78635193 1648776 40 duplication control 
17 p13.1 10119922 10423933 304011 40 duplication control 
17 q12 34815551 36245768 1430217 45 duplication patient 
19 
q13.41-
q13.42 
52495380 54803022 2307642 50 deletion control 
20 p13 2308942 2725678 416736 40 duplication patient 
20 p13 3183919 3641868 457949 40 duplication patient 
21 q21.3 27484463 27852668 368205 40 duplication patient 
22 q11.21 18222118 18606947 384829 45 duplication control 
22 
q11.21-
q11.22 
20740778 21806401 1065623 45 duplication control 
X 
p22.33-
q28 
2700157 154780283 152080126 15 deletion patient 
 
 
Our data displays that mosaic duplications (87,5%) are more frequent than mosaic deletions 
(12,5%). The most frequent chromosome of event observed was chromosome 2 (12,5%) for 
patient cohort and chromosome 22 (8,3%) for control cohort. Average lengths for mosaic 
duplications in patients (754 kb) and in controls (799 kb) were the same. The abnormal cell 
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proportions were between 40-45% for mosaic duplications and 15-50% for mosaic deletions. 
Five of the mosaic duplication events in patients (see Table 4, bolded) are the same with the 
CNV regions described in previous study (with a range of 40-45% degree of mosaicism). 
Detected mosaic CNVs were examined for genes relevant to POF with using UCSC Genome 
Browser database
2
. 
 
 
Figure 9. Illustration of mosaic monosomy of chromosome X (BAF values for p22.11-
q28) from patients group. Mosaic monosomy is detected when LRR (top) shows a decrease 
from normal copy number state. In addition, the BAF (bottom) shows a split from the 
intermediate value of 0.5 and indicates the percent of abnormal population of cells. Loss of 
and A allele, results in a shift of the frequency towards 0%, while loss of a B allele results in a 
shift towards 100% and the percent of mosaicism can be calculated from the relative shifting 
of the BAF values. 
 
 
Mosaic copy-neutral events can also be captured by the detection of BAF deviations from the 
expected value of 0.5 and the LRR value is not represented. The degree of UPD was 
determined as described previously by Conlin et al. (Supplement 3). We were able to detect 
total of 241 mosaic UPD cases, ranging in length 14,6 kb to 63 Mb, but only the changes 
larger than 1 Mb (N=24) were considered for further analysis. Half of these events (N=13), 
were located around the centromeric or telomeric regions of the chromosome (data not 
shown). Out of remaining 11 mosaic UPD events for further investigation, six occured in 
patients and five in controls (Table 5, see below). The abnormal cell proportions for UPD 
events ranged between 10-60%. Full chromosome mosaic UPD occured in chromosome 13 in 
one of the patients (Figure 10, see below) with 30% abnormal cells. 
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Table 5. Summary of mosaic uniparental disomy (UPD) findings larger than 1 Mb in 
patients and controls. White rows are representing the UPD regions from patients and blue 
ones from controls. The values for start and end point are from BAF values.  
 
Chr Band Start Stop Length (bp) 
Mosaic UPD % 
of abnormal cells 
Subject 
2 p11.2 86406556 88315993 1909437 15% control 
3 p21.31-p21.1 49701298 53457291 3755993 10% control 
6 p22.2-p21.33 26405835 31427139 5021304 50% control 
6 p22.1-p21.33 29230577 31000042 1769465 60% patient 
6 p22.1-p21.32 29788770 32595060 2806290 40% patient 
6 p21.33-p21.32 31000042 32680122 1680080 55% patient 
10 q11.21-q11.22 45478092 47703869 2225777 30% patient 
13 q12.12-q34 23162926 114878438 91715512 30% patient 
14 q32.33 104581072 107287663 2706591 10% patient 
16 p13.11 15129970 16291971 1162001 30% control 
19 q13.2-q13.31 42463050 43864419 1401369 30% control 
 
 
 
 
Figure 10. Output of mosaic UPD event in chromosome 13. The LRR (top) is consistent 
with normal copy number. The BAF plot (bottom) demonstrates a shift in genotype 
frequencies and the percent of mosaicism for the abnormal cell line could be estimated at 
30%. In 13q14.3 is also detected a deletion. 
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2.4 Discussion 
Numerical and structural chromosome alterations, including deletions, duplications, 
uniparental disomy and translocations, may cause a wide variety of genetic disorders with 
different severity. However, some of  these variations  may also be benign within a population 
(Feuk et al. 2006). Identifying DNA variants that contribute to a disease or syndrome is a key 
objective in human genetics. State-of-the-art genome technologies such as SNP microarrays 
and next generation sequencing have drastically enhanced our understanding about the 
underlying mechanisms of genetic anomalies as well as genetic heterogeneity within and 
between individuals. Along with technological advances, new algorithmic methods are crucial 
in identifing genetic variations across large datasets. Although many algorithmic methods 
have been designed to detect CNVs, but they are not accurate enough to detect CN-LOH and 
somatic mosaic aberrations, in particular aberrations with low degree of mosaicism. Within a 
population of cells originating from a single zygote, any post-zygotic somatic change may 
results in mosaicism, in which a subset of cells harbors a different genetic variant. 
Mosaicism is a biological phenomenon that indicates the presence of two or more 
chromosomally different cell lines in an individual arising from a single zygote (Strachan and 
Read, 2011). The underlying mechanism of mosaicism formation involves a nondisjunction 
error during a mitotic cell division or during meiosis followed by a post-zygotic correction of 
aneuploidy. The implication of genetic mosaicism for disease phenotypes is difficult to 
predict in many cases, since it is dependent upon timing of the mutation event, cell type or 
types affected and distribution of genetically aberrant cells. However, mosaic forms of disease 
are generally associated with milder phenotypes compared to non-mosaic aberrations. 
SNP microarray data enables quantitative measurement of aberrant cell population via  
the B-allele frequency (BAF) values. Mosaic events can be captured by analysing SNP array 
data, especially from assessing multiple clusters of heterozygous alleles showing BAF and 
LRR values different from those expected for regular heterozygous deletions, duplications or 
loss of heterozygosity (LOH) events. Interestingly, a number of studies demonstrate that 
structural variants occurring in mosaic forms are more frequent than expected, and thus they 
may play a relevant role in human diversity and disease susceptibility (Conlin et al. 2010; 
Jacobs et al. 2012; Laurie et al. 2012; Razzaghian et al. 2010; Vattathil and Scheet 2016). 
In this study, DNA of 345 individuals with spontaneus POF and 242 individuals with 
iatrogenic POF have been used to investigate for evidence of copy number variations and 
somatic mosaicism using Illumina genome-wide SNP array data and a novel computational 
approach enabling an accurate detection of (mosaic) genetic alterations. The presence of 
CNVs in phenotypically selected premature ovarian failure patients from Estonian population-
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based biobank has been investigated in a previous study (Tšuiko et al. 2016), using two 
independent Hidden Markov Model-based algorithms, QuantiSNP (Colella et al. 2007) and 
PennCNV (Wang et al. 2007). Here, we applied a novel computational algorithm, inspired 
from haplarithmisis concept (Zamani Esteki et al. 2015) and compared the two studies.  
Copy number alterations in human genomic DNA are most likely the cause of 
different rare or complex disorders (Vulto-van Silfhout et al. 2013). Premature ovarian failure 
is highly heterogeneous disease with strong genetic component. We identified four patients 
with monosomy X and it is known that Turner syndrome (45,X) is the most common 
congenital cause of POF (Schlessinger et al. 2002). X monosomy without mosaicism is more 
typically found in primary amenorrhea and according to phenotype information, three of our 
patients had absence of menstruations, but in one of these Turner cases occurred amenorrhea 
at the age of 30. 
From copy number variation analysis, performed with our method, we investigated a 
total of 23 non-overlapping CNVRs from patient cohort. In comparison with previous study, 
which found 55 rare microdeletion or microduplication regions (see Tšuiko et al. 2016, 
Supplementary), our method was able to detect 70,6% of the same regions and eleven novel 
regions among the same population of patients. However, 29,4% of the regions remain 
undetected. We did not find any susceptibility genes among these 23 regions relevant to POF 
pathogenesis. According to the point that CNVs from spontaneous premature ovarian failure 
patients were already examined before, we have to take into consideration many aspects 
between these studies that may lead to different results: (1) the algorithmic methods to detect 
genetic alterations were different; (2) the interpretation of CNVs were performed with 
different strategies and (3) the controls cohorts were not accordance. Despite of these 
annotations, the comparison results were quite expected and the main goal of this study was 
primarily directed for detection of mosaic abnormalities. 
We identified 24 non-overlapping mosaic copy number variation regions (>100 kb), 
15 of them among patients and nine among controls. It was interesting that mosaic 
duplications (87,5%) were much more presented than mosaic deletions (12,5%). Among 
mosaic alterations, the most significant finding of this study was mosaic monosomy for X 
chromosome, where the terminal part of a short arm is not mosaic (see Figure 9). According 
to phenotype information, the patient had relatively short stature (156 cm) and menopause 
occurred at the age of 30. With regard to short stature, it has been suggested that the SHOX 
gene (MIM *312865)
3
 in pseudoautosomal region (PAR1) is the major player and that 
haploinsufficiency of this gene leads to the growth failure seen in Turner syndrome (Rao et al. 
1997). We hypothesize that this particular monosomy may have originated from normal XX 
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cells with CN-LOH in the terminal part of short arm, where the SHOX gene is located, which 
probably initiated X monosomy in a subset of cells. The proportion of abnormal cells in this 
particular case was 15%. The low percentage of cells affected may indicate that this 
individual with mosaic monosomy X will have a milder phenotype than those with complete 
monosomy X. Mosaic TS patients are more likely to experience normal pubertal 
development, regular menstrual cycles and to conceive spontaneously compared to those with 
45,X monosomy (El-Mansoury et al. 2007). Our patient had normal menstruations between 
19-30 years of age and no other clinical features for Turner stigmata was not observed. 
Mosaic monosomy could either arise by mitotic non-disjunction in a diploid embryo leading 
to monosomy in a subset of cells, or monosomy rescue in some cells of a monosomic zygote 
early in development (Conlin et al. 2010).  
Other mosaic changes were relatively small (approximately 885 kb in length). Five of 
the mosaic alterations were in the same regions as described in previous study. Three of these 
regions involved potential candidate genes for POF, two of them (SGOL2 in 2q33.1 and 
LHX1 in 17q12) are consistent with the findings of Tšuiko et al. In our opinion, these five 
regions detected as mosaic CNVs are more precise because the methods used in previous 
study can not detect mosaic aberrations. This discovery leads us to argue about the proportion 
of mosaic events among detected CNV results. Extrapolating our results, the difference would 
be as high as 9.1%. These observations are concordant with Rodriguez-Santiago et al., who 
suggested in their study that the occurrence of mosaic events is underestimated because of 
deficiency of common detection methods. They also brought out, that is plausible that some 
of the CNVs registered in the Database of Genomic Variants might correspond to mosaic 
rearrangements. Thus, optimization of the analysis of data obtained with SNP arrays, as well 
as the development of novel algorithms for the analysis of low-degree mosaicism is required 
to improve the accurate detection of these events in human populations (Rodríguez-Santiago 
et al. 2010). 
In the mosaic deletion in chromosome 2 (chr2:36,775,797-38,580,233) is located the 
CYP1B1 (Cytochrome P450 1B1) gene (MIM *601771)
3
, which is involved in estrogen 
hydroxylation (Nishida et al. 2013) and with CYP1A1 (Cytochrome P450 1A1) it is the 
primary gene involved in estrogen metabolism (Tsuchiya et al. 2005). Affecting this gene, 
higher levels of estrogens throughout the reproductive life are believed to exist (Hanna et al. 
2000), but the way in which this would affect the ovarian follicular pool remains to be 
elucidated. However, previous investigations showed that CYP1B1 polymorphisms are 
unlikely to influence the age at menopause (Hefler et al. 2005; Long et al. 2006). 
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Uniparental disomy (UPD) is the presence of a chromosome pair derived only from one 
parent present in a disomic cell line (Liehr 2010). In this study, we identified 24 mosaic UPD 
events larger than 1 Mb and for further analyse was considered eleven of these regions. 
Remaining 13 mosaic UPD events were located near centromere (11) or telomere (2). For 
example, copy-neutral telomeric events are theoretically expected if mitotic recombination 
represents DNA repair occurring secondary to a double strand break, which is the generally 
favored mechanism. Previous studies confirm the strong correlation of segmental UPD with 
telomeric regions (Kotzot 2008). Breakpoint analyses of regions surrounding mosaic events 
might aid in understanding mechanisms responsible for event initiation, but the current 
resolution of event boundaries in SNP microarrays is limited as a result of insufficient probe 
density (Machiela et al. 2015). Of the eleven mosaic UPD cases, six occurred in patients and 
five in controls. The abnormal cell proportions for these UPD events ranged between 10-60%. 
If we take into account all the detected mosaic UPD events (N=241), these findings are also 
consistent with other studies that implicate mosaic copy-neutral UPDs as the majority of 
detected mosaic events (Machiela et al. 2015; Rodríguez-Santiago et al. 2010). Mosaicism for 
segmental UPD most probably arises through mitotic recombination or alternatively by 
chromosome breakage and repair, in which the DNA sequence from one allele is copied 
across to replace the other allele to generate homozygosity (Biesecker and Spinner 2013). 
SNP arrays has the advantage of precise mapping of segmental UPD regions, but this 
technology can only identify isodisomic cases (isodisomic regions) (Conlin et al. 2010). In 
this study, both patients and controls were detected the same amount of segmental mosaic 
UPD events. 
Full chromosome mosaic UPD (isodisomy) occured in chromosome 13 in one of the 
patients (see Figure 10) and using the shift in allele frequencies the percent of mosaicism for 
the abnormal cell line was estimated at 30%. The origin of UPD often entails meiotic 
nondisjunction followed by a mitotic rescue event, but the possibility of crossing-over of 
homologs and missegregation of translocated chromosomes and other complex events are also 
possible (Kotzot 2008). The possible mechanism by which this particular chromosome 13 
mosaic UPD occurred is probably due to post-fertilization error, occurrence of mitotic 
nondisjunction and the subsequent duplication of the remaining chromosome. 
Mitotic recombination and gene conversion can result in acquired uniparental disomy 
(aUPD), where loss of heterozygosity has occurred without loss of genomic material and both 
alleles of a gene are derived from one parent. This is also called copy-neutral loss of 
heterozygosity (CN-LOH) and leads to the generation of daughter cells with reciprocal 
chromosomal products (Fitzgibbon et al. 2005). CN-LOH does not alter the copy number of 
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affected chromosomal segment and are detectable with BAF values of allelic imbalances. In 
this study, CN-LOH events were explored by visual inspection of the profiles deduced by the 
algorithm. Both patients and controls showed relatively high amount of copy-neutral events 
across the genomes, but we could not find a significant difference between these cohorts. Our 
results shows diversity between events among chromosomes, for example in our study in 
chromosome 9 we observed the least CN-LOH events, but in Laurie et al. chromosome 9 has 
the highest amount of occurrence (see Laurie et al. 2012, Supplementary Figure 9). Even 
though, the other chromosomes showed approximately the same rate of events.  
In addition, we observed relatively large CN-LOH regions in chromosomes 2, 3, 7, 17 
and 22 in one of the patients. CN-LOH is not expected to cause abnormalities unless genes on 
affected chromosome loci are subject to genomic imprinting, which is the monoallelic 
expression that is dependent on the allele’s parental origin. When aUPD occurs in a region 
containing an imprinted domain, cells will inherit either two active or two repressed copies, 
leading to an abnormal dosage of these imprinted gene products (Lapunzina and Monk 2011). 
Mostly, CN-LOH has been shown to be involved in the development of cancers and 
developmental disorders. The list of conditions that have been associated with CN-LOH is 
continuously growing (Makishima and Maciejewski 2011; Tuna et al. 2009). In addition, this 
particular patient, has relatively large (~62,5 Mb) CN-LOH region in chromosome 7 (q21.2-
q36.2), encompassing two strong candidate genes for POF (OMIM nomenclature for POF5 
(NOBOX) and POF8 (STAG3)
3
. We might assume that this LOH is possible cause of POF 
condition as both genes are located in this region, but additional molecular validation is 
needed for confirmation. 
In summary, it is highly possible that the mosaic occurrence of genomic variants may 
have been missed previously with the standard methods applied to CNV detection with SNP 
arrays. In the light of recent findings about the presence of detectable somatic mosaicism, our 
method is certainly advantagous in detecting low-grade mosaicism and resolve the 
mechanistic origin of constitutional genetic anomalies detected in multi-cell DNA samples. If 
we consider for calculation all the detected mosaic events larger than 2 Mb like many large-
scale studies have performed, then the presence of detectable clonal mosaicism in our study is 
3.2%. 
As mosaicism is becoming an increasingly frequent observation, there are many issues 
that need to be aware of: (1) first and foremost, mosaicism has been underestimated within the 
population. Mutations accumulate in individuals over their lifetime that may not have a 
phenotypic effect and we surely should expect to find mosaicism in phenotypically normal 
individuals; (2) similarly, loss of the X chromosome might exist in mosaic form, which means 
 37 
that having some 45,X cells does not mean the patient has Turner syndrome. It is therefore 
important to understand that finding mosaicism does not make it causal of the phenotype 
under investigation; (3) if the mutant cells do not have growth advantage over the normal 
cells, then it is related to reduced percentage of detectable mosaicism associated with a more 
severe phenotype. Mosaicism may have a greater impact on the phenotype when expressed in 
one tissue over another and it is more likely occurring earlier during development. 
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SUMMARY 
 
Genetic variation between individuals has been extensively investigated, but differences 
between tissues within individual are far less understood. It is commonly assumed that all 
healthy cells that arise from the same zygote possess the same genomic content. However, 
somatic mosaicism arised from post-zygotic mutations for copy number and copy-neutral 
chromosomal rearrangements has been recently identified as a relatively common source of 
genetic variation between normal individuals, but its prevalence in population is poorly 
defined or underestimated. Despite numerous techniques available to be applied, low-grade 
mosaicism remains a difficult issue in both clinical diagnostics and research. At this point, it 
is worth to add that there is a growing concern in the field about whether some CNVs 
categorized as germline-acquired mutations in biobanks are actually somatically acquired 
alterations. 
 Aims of this thesis was to review the basic forms of mosaic abnormalities (deletions, 
duplications, UPDs and CN-LOHs) with their possible mechanisms of post-zygotic formation 
during mitosis. We introduced the common detection methods and demonstrated the results 
from recent genome-wide array approaches to detect mosaic alterations. In practical part of 
the thesis, we analysed genotype data of premature ovarian failure (POF) patients and controls 
with novel algorithmic method for detection of mosaic structural rearrangements. We found 
mosaic aberrations in 8.2% of samples, including 23 mosaic copy number variation (CNV) 
regions, one mosaic X monosomy and 24 (larger than 1 Mb) mosaic uniparental disomy 
(UPD) events. In addition, we were able to investigate 23 novel CNVs among patients. 
Reanalysis of the previously assessed SNP array analysis with POF patients demonstrated that 
there are hidden genomic mosaic events that cannot be detected by using standard detection 
methods. Based on the information provided from this study, it is apparent that some cases of 
previously detected CNVs may contribute mosaic form of alteration.  
It is still largely unknown exactly what types of environmental or genetic factors are 
responsible for the development of detectable human clonal mosaicism and therefore, in this 
genetic area is plenty of more to discover. We emphasize that somatic mosaicism should be 
considered as a form of inter- and intraindividual genetic variation. 
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Geneetilised aberratsioonid enneaegse ovariaalpuudulikkusega patsientidel 
Katre Teearu 
KOKKUVÕTE 
 
Tänapäeval arvatakse, et genoom on kõigil inimestel 99,9 protsenti identne ja ainult 0,1 
protsenti erinevust teeb meid üksteisest niivõrd erinevaks. Just see väga väike osa DNA-st on 
meditsiiniteaduse peamisi prioriteete, et uurida, kuidas geneetiline varieeruvus avaldub ning 
seeläbi põhjustab erinevaid haiguseid. Inimorganism koosneb umbes 1014 rakust ja seega ei 
ole üllatav, et DNA replikatsioonil või rakujagunemiste käigus inimese eluea jooksul tekib 
vigu, mis genereerivad „personaalse“ genoomiga rakke. Üks osa inimkonna varieeruvusest on 
seletatud mosaiiksusega, mis on bioloogiline fenomen, kus viljastamisjärgselt esineb 
üksikindiviidi erinevates rakupopulatsioonides erineva genotüübiga rakke. Mosaiiksust on 
pikka aega peetud inimestevahelise ning ka -sisese geneetilise varieeruvuse põhjuseks. 
Mosaiiksed struktuursed ümberkorraldused genoomis võivad avaldada mõju indiviidi 
fenotüübile ning olla seeläbi erinevate haiguste põhjuseks, kuid see sõltub spetsiifilisest DNA 
regioonist, arenguetapist ja mõjutatud rakkudest. 
 On teada, et kolm peamist tüüpi struktuursed geneetilised ümberkorraldused, nagu 
deletsioonid, duplikatsioonid ja koopiaarvu neutraalsed heterosügootsuse kaotanud alad 
võivad tekkida ka postsügootiliselt. Ülegenoomsete genotüpiseerimiskiipide andmete analüüs 
koos arvutuslike meetoditega võimaldavad detekteerida kromosomaalseid aberratsioone kui 
ka somaatilisi mosaiikseid muutuseid. Enneaegne ovariaalpuudulikkus (POF) on 
multifaktoriaalne haigus, mis viib viljatuseni reproduktiivses eas naisi aastaid enne 
loomulikku menopausi. Olenemata haiguse heterogeensest etioloogiast, mitmed uuringud 
kinnitavad, et POFi esilekutsuvatest mehhanismidest on geneetikal tugev roll. 
 Käesoleva magistritöö eesmärgiks oli anda kirjandusel põhinev ülevaade peamistest 
mosaiiksuse vormidest erinevate struktuursete ümberkorralduste puhul ning tuua välja nende 
võimalikud tekkemehhanismid postsügootilistes protsessides. Samuti tutvustada, kuidas 
erinevate meetoditega on võimalik mosaiiksust detekteerida ning milliseid suuremahulisi 
uuringuid selles valdkonnas on läbi viidud. Töö praktilises osas teostati kogu genoomi 
hõlmav uuring, avastamaks mosaiikseid ümberkorraldusi enneaegse ovariaalpuudulikkusega 
patsientidel kui ka kontrollindiviididel. Kasutades genotüpiseerimiskiipide andmeid ja 
rakendades uut algoritmilist meetodit, tuvastati 8,2%-l valimist mosaiikseid aberratsioone, 
nende hulgas 23 koopiaarvu varianti, üks X kromosoomi monosoomia ja 24 (>1 Mb) 
uniparentaalse disoomia juhtu. Lisaks avastati patsientide hulgas 23 uudset koopiaarvu 
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variatsioonide regiooni. Korduvanalüüs enneagse ovariaalpuudulikkusega patsientidel näitas, 
et leidub peidetud genoomseid mosaiikseid aberratsioone, mida ei ole võimalik avastada 
standardmeetodeid kasutades. Uuringu tulemustest saab järeldada, et eelnevalt tuvastatud 
koopiaarvu variatsioonide hulgas võib mõningatel juhtudel ilmneda mosaiikseid vorme. 
 Siiani on täpselt teadmata, millised geneetilised- või ka keskkonnafaktorid vastutavad 
inimese mosaiiksete rakkude arengu eest ja seetõttu on antud geneetilisel areenil veel küllalt 
avastamisruumi. 
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SUPPLEMENTS 
Supplement 1 
Overview of microarray studies investigating detectable clonal mosaicism.  
 
Reference Platform Variation type Tissue 
Number of 
samples 
Number of mosaic 
anomalies 
Frequency 
(%) 
Subjects 
(Conlin et al. 
2010) 
SNP microarray CNV, LOH blood, fibroblasts 2019 23 (+1 chimera) 1.1 
childrens with 
developmental 
delay 
(Rodríguez-
Santiago et al. 
2010) 
SNP microarray CNV, UPD blood, buccal 1991 
34 (+8 mosaic 
trisomy) 
1.7 
(autosomes) 
bladder cancer 
cases 
(Jacobs et al. 
2012) 
SNP microarray CNV, CN-LOH blood, buccal 57 853 517 0.89 
31,717 cancer 
cases (GWAS) 
(Laurie et al. 
2012) 
SNP microarray CNV, CN-LOH blood, buccal 50 222 514 
<0.5% 
(0-50 y); 
2-3% (>50 y) 
GWAS subjects 
(Pham et al. 
2014) 
aCGH CNV blood 10 362 57 0.55 
Patients with 
cognitive 
impairment 
(Machiela et 
al. 2015) 
SNP microarray CNV, UPD blood, buccal 127 179 1315 
0.73 
(autosomes) 
GWAS subjects 
(Vattathil and 
Scheet 2016) 
SNP microarray CNV, CN-LOH blood, buccal 31 100 1087 3.5 GWAS subjects 
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Supplement 2 
 
 
Expected B-allele frequencies and respective degree of mosaicism for deletion/duplication due to mitotic nondisjunction. 
               
    
Percentage of abnormal cell line 
       Cell line 1  BAF Cell line 2 BAF 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 
 a 0 aaa 0 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 
 a 0 aab 0,333 0,000 0,024 0,048 0,070 0,091 0,111 0,130 0,149 0,167 0,184 
 a 0 abb 0,333 0,000 0,024 0,048 0,070 0,091 0,111 0,130 0,149 0,167 0,184 
 b 1 baa 0,333 1,000 0,951 0,905 0,860 0,818 0,778 0,739 0,702 0,667 0,633 
 b 1 bba 0,333 1,000 0,951 0,905 0,860 0,818 0,778 0,739 0,702 0,667 0,633 
 b 1 bbb 1 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 
 Cell line 1  BAF Cell line 2 BAF 50% 55% 60% 65% 70% 75% 80% 85% 90% 95% 100% 
a 0 aaa 0 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 
a 0 aab 0,333 0,200 0,216 0,231 0,245 0,259 0,273 0,286 0,298 0,310 0,322 0,333 
a 0 abb 0,333 0,200 0,216 0,231 0,245 0,259 0,273 0,286 0,298 0,310 0,322 0,333 
b 1 baa 0,333 0,600 0,569 0,538 0,509 0,481 0,455 0,429 0,404 0,379 0,356 0,333 
b 1 bba 0,333 0,600 0,569 0,538 0,509 0,481 0,455 0,429 0,404 0,379 0,356 0,333 
b 1 bbb 1 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 
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Supplement 3 
 
 
Expected B-allele frequencies and respective degree of mosaicism for segmental UPD. 
  
 
 
            
    
Percentage of abnormal cell line 
       Cell line 1  BAF Cell line 2 BAF 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 
 aa 0 aa 0 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 
 ab 0,5 aa 0 0,500 0,475 0,450 0,425 0,400 0,375 0,350 0,325 0,300 0,275 
 ab 0,5 bb 1 0,500 0,525 0,550 0,575 0,600 0,625 0,650 0,675 0,700 0,725 
 bb 1 bb 1 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 
 Cell line 1  BAF Cell line 2 BAF 50% 55% 60% 65% 70% 75% 80% 85% 90% 95% 100% 
aa 0 aa 0 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 
ab 0,5 aa 0 0,250 0,225 0,200 0,175 0,150 0,125 0,100 0,075 0,050 0,025 0,000 
ab 0,5 bb 1 0,750 0,775 0,800 0,825 0,850 0,875 0,900 0,925 0,950 0,975 1,000 
bb 1 bb 1 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 
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Supplement 4 
 
Figures of CN-LOH regions with approximate sizes from different chromosomes (chr 2, 3, 7, 
17 and 22) in one of the patients.  
 
 
CN-LOH in 2p24.1-p21 (approximate size 20.5 Mb). 
 
 
 
CN-LOH in 3p12.1-q13.2 (approximate size 28.5 Mb). 
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CN-LOH in 7q21.2-q36.2 (approximate size 62.5 Mb). 
 
 
 
CN-LOH on 17q12-q25.3 (approximate size 46.7 Mb). 
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CN-LOH in 22q11.21-q12.1 (approximate size 10.8 Mb). 
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